Decoy Therapeutics enters $3.5 million PIPE priced at USD 5.91 per share

• Decoy Therapeutics entered a PIPE with one healthcare-focused institutional investor for USD 3.5 million in upfront gross proceeds.
• Common stock or pre-funded warrants priced at USD 5.91 per share; closing expected on or about June 29, 2026.
• Milestone-based Series A, B, C warrants could add about USD 17.5 million in gross proceeds if exercised.
• Proceeds earmarked to advance the lead asset into clinical trials.
• Securities sold in an unregistered private placement under Section 4(a)(2) or Regulation D; resale registration statement due within 15 days post-close.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606262011PR_NEWS_USPR_____NE93658) on June 27, 2026, and is solely responsible for the information contained therein.